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Abstract 
Cerebral blood flow (CBF) is impaired in acute liver failure (ALF) and the results are often 
inconclusive due to complexity of the underlying mechanism. Regulation of CBF depends at 
least partially on variations in the local brain L-arginine concentration and/or its metabolic 
rate. In ALF, other factors, like an increased concentration of asymmetric dimethylarginine 
(ADMA), an endogenous nitric oxide synthase inhibitor and elevated level of L-glutamine, 
may contribute to CBF alteration. The present study demonstrated strong differences in the 
reactivity of the middle cerebral arteries and their response to extravascular L-arginine 
application between vessels isolated from rats with thioacetamide (TAA)-induced ALF and 
control animals. Our results also showed the decrease in the cerebral perfusion in TAA rats 
measured by arterial spin labeling perfusion magnetic resonance. Subsequently, we aimed to 
investigate the importance of balance between the concentration of ADMA and L-arginine in 
the CBF regulation. In vivo, intraperitoneal L-arginine administration in TAA rats corrected: 
i) decrease in cerebral perfusion, ii) decrease in brain extracellular L-arginine/ADMA ratio 
and iii) increase of brain L-glutamine concentration. Our study implicates that impaired 
vascular tone of cerebral arteries is most likely associated with sustained exposure to high 
ADMA and L-glutamine levels resulting in limited availability of L-arginine and might be 
responsible for reduced cerebral perfusion observed in ALF. 
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Introduction 
The accumulation of neurotoxic substances in the brain, due to acute or chronic liver 
failure (ALF vs. CLF), results in neurological alterations known as hepatic encephalopathy 
(HE) (Butterworth 2003; Felipo 2013). The pathomechanism of HE remains complex, 
however, the general consensus is that neurotoxic effects of blood-derived ammonia in the 
brain compounded by central and systemic inflammatory processes play a dominant role 
(Butterworth 2013; Liere et al. 2017). It is generally assumed that intra-astrocytic 
accumulation of glutamine, a product of ammonia detoxification via enzymatic conversion of 
glutamate by glutamine synthetase (Norenberg and Martinez-Hernandez 1979), directly 
contributes to brain edema and other clinical manifestations of HE (Butterworth 2013; 
Albrecht et al. 2010). 
Neurological dysfunctions accompanying HE progression may result from low cerebral 
oxygen metabolism which is the primary event contributing to dysregulation of cerebral blood 
flow (CBF) (Felipo 2013; Iversen et al. 2009; Iversen et al. 2014; Zheng et al. 2012). 
Importantly, CBF alteration related to endothelial dysfunction associated with nitric oxide 
(NO) signaling is relatively less examined aspect of HE pathology (Palenzuela et al. 2016). 
Depending on etiology and time point in disease progression, cerebral perfusion has been 
found both increased or decreased (Iversen et al. 2009; Zheng et al. 2012; Jalan et al. 2004). 
This discrepancy raises difficulties in the choice of treatment strategy. Importantly, regional 
CBF differences were also observed
2
, however, an explanation of this phenomenon is not 
known. 
CBF, which has the potential of being used as the indicator of brain dysfunction (Becker et al. 
1996; Iversen et al. 2009), is related to L-arginine metabolism, therefore, synthesized and/or 
released nitric oxide (NO) is arguably the most important endogenous vasodilator in the 
regulation of cerebral perfusion (Keynes and Garthwaite 2004). Asymmetric dimethylarginine 
(ADMA), an endogenous inhibitor of NO synthesis, is present in a relatively high 
concentration in the brain (Teerlink et al. 2009). Thus, one of physiological effects of ADMA 
might be to control the cerebrovascular reactivity and CBF in resting conditions. Since 
elevated ADMA concentrations were frequently documented in patients with HE and animal 
models of HE, as reviewed by Czarnecka et al. (Czarnecka et al. 2017), a direct response of 
HE-affected vessels and a possible role of ADMA in CBF regulation in this pathology, have 
to our knowledge never been assessed. Importantly in this context, topical application of 
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ADMA in the rat brain constricted the basilar artery (Faraci et al. 1995). In turn, exogenously 
added ADMA caused concentration- and endothelium-dependent contraction of the human 
middle cerebral artery (MCA) (Segarra et al. 1999) which was prevented by L-arginine (Chen 
et al. 2012). L-arginine was reported to improve vascular function by overcoming deleterious 
effect of ADMA (Böger and Ron 2005). Furthermore, systemic administration of L-arginine 
exerted a beneficial effect on the cortical CBF in the experimental stroke (Willmot et al. 
2005) and brain trauma (Lundblad and Bentzer 2007). 
L-arginine availability for NO synthesis in the brain may be regulated by elevated 
concentration of glutamine (Kawaguchi et al. 2005). Previously reported data indicated that 
L-glutamine acted by inhibition the L-citrulline to L-arginine recycling, thereby limiting L-
arginine availability for NO production. In support of this concept, an excess of L-arginine 
overcame the inhibitory effect of L-glutamine on vascular reactivity as demonstrated in vivo 
(Okada et al. 2000). In addition, pharmacologically increased extracellular L-glutamine in the 
brain reduced NO and subsequently cGMP production both, in healthy and ammonia-exposed 
rat brain (Hilgier et al. 2009). Accordingly, pre-incubation with L-glutamine stimulated L-
arginine efflux from rat brain slices (Zielińska et al. 2011) via a mechanism involving y+L 
transport system (Zielińska et al. 2012; 2015). 
In the present study we compared the basal reactivity of isolated MCAs and cerebral 
perfusion of control and ALF rats. The MCA was chosen for this study because as a resistance 
vessel it participates in the regulation of cerebral blood flow (Faraci and Heistad 1990). The 
analyses were conducted in a well-established rat model of ALF induced by intraperitoneal 
administration of the hepatotoxin, thioacetamide (TAA), which reproduces most of the 
cerebral metabolic changes and symptoms observed during ALF. Importantly, the elevated 
concentration of ADMA and L-glutamine in the brain and plasma of TAA rats have been 
previously documented (Hilgier et al. 1994; 1996; Czarnecka et al. 2017; Milewski et al. 
2015; 2017). 
Therefore, the specific aims of this study were to investigate in the TAA-induced rat model of 
ALF: (i) vasodilatory status and reactivity of the isolated MCAs to extravascular L-arginine; 
(ii) extracellular brain concentration of amino acids and ADMA after ip infusion of L-
arginine; (iii) CBF changes induced by ip administration of L-arginine. 
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Materials and methods 
Animals 
The studies were conducted on 36 male Sprague–Dawley rats, animal colony supplied by the 
Animal House of Mossakowski Medical Research Centre, Warsaw, Poland of initial body 
weight from 220 to 275 g kept 2-3 under standard laboratory conditions in cages model 
1291H Eurostandard Type III H at room temperature (22
o
 C) under an artificial light/dark 
cycle (12/12 h), with free access to standard laboratory food and tap water. All procedures 
were conducted in accordance with the National Institutes of Health Guidelines for the Care 
and Use of Laboratory Animals, and received a prior approval from the Bioethics 
Commission of the Academy, as compliant with Polish Law (of January 21, 2005). The 
experimental procedures were approved by the 4
th
 Local Ethics Committee for Animal 
Experimentation, Warsaw, Poland. All efforts were made to reduce the number of animals 
and to minimize their suffering. The study complies with the ARRIVE guidelines for 
reporting animal research. All procedures on animals were carried out in a randomized 
manner. This study was not pre-register d. 
Study design and animal groups 
 
Animals were randomly divided into two experimental groups: control (16 rats) and acute 
liver failure (20 rats). All further experiments were performed 72 hours after the last 
thioacetamide (TAA)/saline dose. Isolated cerebral artery studies were conducted on 5 control 
and 8 TAA rats, microdialysis study was carried out on 5 control and 5 TAA rats and ASL-
MRI perfusion measurement on 6 control and 7 TAA rats, respectively. 
Number of animals was determined based on pilot studies which provided statistically 
signiﬁcant differences between test and control. 
Acute liver failure model 
HE was induced by three intraperitoneal (ip) injections of TAA (Sigma-Aldrich, Steinheim, 
Germany) (300 mg/kg body weight.) at 24 h intervals (Hilgier and Olson 1994). Control rats 
were administered i.p. with saline solution according to the analogical scheme.  
Isolated cerebral artery studies 
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Middle cerebral arteries (MCAs) were isolated from the brain of control and TAA rats and 
located in an organ chamber filled with physiological saline solution buffered with MOPS (3-
(N-morpholino) propanesulfonic acid), (MOPS-PSS) with 1% dialyzed bovine serum albumin 
(BSA) addition (pH 7.4 adjusted by NaOH), as it was described in detail previously 
(Aleksandrowicz et al. 2017). The organ chamber was placed at the stage of inverted 
microscope (CKX41, Olympus, Germany) connected with a video camera and a monitor for 
analysis of inner diameters of the arteries. The vessels were perfused with MOPS-PSS 
containing 1% BSA at a transmural pressure of 80 mm Hg. Extraluminal fluid was switched 
to MOPS-PSS without BSA, heated to 37°C using a water bath and the medium was 
exchanged at a rate of 20 mL/min with the help of a peristaltic pump (Masterflex, Cole 
Parmer, USA). After developing myogenic tone, i.e. a contraction by about 30% - 40% of the 
initial diameter, smooth muscle cell function was tested by increasing extraluminal K
+
 ion 
concentration from 3 mM to 20 mM. MCAs which did not develop myogenic tone were 
excluded from further studies.  
The responses of the isolated, cannulated and pressurized MCAs to extravascular 
administration of L-arginine (100 µM) were assessed after 20 min of continuous perfusion in 
few variants. The dose of L-arginine was chosen based on the available literature (Kajita et al. 
1995; Tsikas et al. 2000). The arteries from control (untreated with TAA) rats were studied: 
(a) in the standard MOPS - PSS containing: 3.0 mM MOPS, 145.0 mM NaCl, 3.0 mM KCl, 
2.5 mM CaCl2, 1.5 mM MgSO4, 1.21 mM NaH2PO4, 0.02 mM EDTA, 2.0 mM sodium 
puryvate, 5.0 mM glucose, or (b) MOPS-PSS + 400 µM NH4Cl. The MCAs isolated from 
TAA rats were maintained depending on the experimental variant in the presence of 
ammonium ions and ADMA at concentration equal to those observed in plasma in vivo, 
therefore, the following groups were studied: (c) MOPS-PSS + 400 µM NH4Cl, or (d) MOPS-
PSS + 400 µM NH4Cl + 1 µM ADMA, or (e) MOPS-PSS + 400 µM NH4Cl + 2 µM ADMA. 
The dose of ammonia and ADMA, respectively, were chosen based on the data reporting 
concentrations of these substances in plasma of TAA rats (Milewski et. al. 2015; Milewski 
2017). 
At the end of the experiment, maximal dilation of the vessel was obtained in calcium-free 
MOPS-PSS containing EGTA (3 mM). Percent response of the MCA to L-arginine was 
calculated using the formula: (Dactive − Dbaseline)/(Dmaximum – Dbaseline)*100%, where Dactive is the 
diameter obtained after L-arginine administration, Dbaseline is the diameter prior to application 
of L-arginine, and Dmaximum is the diameter in calcium-free MOPS-PSS with EGTA. Percent 
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tone was calculated as a percent decrease in diameter from the initial diameter measured 
directly after pressurizing. All reagents used in these experiments were purchased from 
Sigma-Aldrich. 
Microdialysis of the rat prefrontal cortex 
Bilateral microdialysis of the prefrontal cortex was performed 24 h after the last TAA 
administration as described previously (Czarnecka et al. 2017). The rats were anesthetized 
with 5% isoflurane (Baxter, Warsaw, Poland) in air within 2 min and then anesthesia was 
maintained during the whole experiment with a 2% isoflurane-air mixture. The body 
temperature was kept at 37.3
o
C by a heating pad controlled by a rectal thermometer. The 
animals were fixed in a Stoelting stereotaxic frame. Briefly, concentric microdialysis probes 
(dialyzing membrane: diameter 0.5 mm; length 3 mm, CMA 12 Elite, CMA Microdialysis, 
Stockholm, Sweden) were implanted bilaterally into the prefrontal cerebral cortex through a 
small hole drilled in the skull (stereotaxic coordinates according to the atlas of Paxinos and 
Watson
37
 were as follow: A/P + 3.0; L +(-) 1.0; D/V -3.5). The probes were perfused with 
artificial cerebrospinal fluid (aCSF), pH 7.4, containing: 126 mM NaCl, 2.4 mM KCl, 1.1 
mM CaCl2, 0.8 mM MgCl2, 0.5 mM KH2PO4, 6 mM glucose (PoCH, Gliwice, Poland) at a 
rate of 2.5 µl/min. Six fractions were collected every 40 min (0-240 min), starting 30 min 
after implantation of the probe. L-arginine (200 mg/kg/3 ml) (Sigma-Aldrich, Steinheim, 
Germany) was injected ip to the anesthetized rat immediately after collecting 2
nd
 fraction (110 
min after implantation of the probe). The dose of L-arginine was chosen based on the data 
reporting the effective doses for stimulation of regional cerebral blood flow (Morikawa et al. 
1992) and preliminary studies which demonstrated that ip injection of 200 mg/kg of L-
arginine resulted in the increased brain extracellular L-arginine concentration up to 5-10 µM. 
Taking into account average in vitro recovery of CMA probes at 15 %, this dose of L-arginine 
increased brain extracellular level to ~100 µM similarly to concentration used in ex vivo 
vascular experiments. After completion of the microdialysis, the anesthetized rats were 
immediately sacrificed by decapitation. Dialysates were stored at -80 ºC until further 
procedures were applied. The researchers analyzing samples were entirely blinded to the 
experimental groups. 
Positive mode electrospray LC–DMS–MS/MS 
HPLC grade ethanol (EtOH), HPLC grade formic acid, gradient grade acetonitryle (ACN), 
LC/MS grade ACN from J.T. Baker (Deventer, The Netherlands) were purchased from 
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Witko. MQ Water was purified with Millipore (Millipore, Bedford, MA, USA) MiliQ 
instrument. 
The extracellular levels of ADMA and L-arginine (ARG) were analyzed using positive mode 
electrospray LC–DMS–MS/MS as described previously (Czarnecka et al. 2017) with a slight 
modification. The sample (20 µl) was mixed with 80 µl of ADMA-D6 and ARG D5 (IS) 
(Sigma-Aldrich, Steinheim, Germany) solution in EtOH (4 ng/ml and 100 ng/ml, 
respectively). The solution was evaporated to dryness under nitrogen, reconstituted with 45 µl 
of acetonitryle (ACN) and transferred to chromatographic vials. Calibration curve was 
prepared using the same buffer as for microdialysis. Eight calibration points were prepared in 
the range from 0.55 ng/ml to 40.7 ng/ml for ADMA, and from 0.12 µg/ml to 3.157 µg/ml for 
ARG. Samples were analyzed using Waters Xevo TQ-S triple quadrupole mass spectrometer 
coupled with Waters Acquity I-Class UPLC. A 3 min HPLC method was set up on Waters 
HILIC equipped with 1.7 µm 2.1 x 100 mm column with thermostatic control at 70
o
C. Mobile 
phase A was composed of 0.025% (trifluoroacetic acid) TFA + 1% acetic acid (AA) in ACN, 
mobile phase B: 0.025% TFA + 1% AA in MQ. Linear gradient from 7% to 25% of phase B 
was used within 2.0 min with the flow rate of 0.65 ml/min. Injection volume was 3 µl. 
Retention time for ADMA was 1.62 min, for ARG 1.67 min. MS detector worked with ESI 
ionization source in MRM mode. Separation was initiated with setting up MRM transitions 
that were highly specific for each compound. Using transitions 203.15 > 46.11 (collision 
energy 14) for ADMA we saw no crosstalk between signals of both compounds as it was 
previously reported in literature (Martens-Lobenhoffer et al. 2012; Zotti et al. 2008). 
Monitored transmission for ADMA-D6 (IS) was 209.19 > 164.19 (collision energy 15). 
Monitored transmission for ARG was 175.12 > 70.03 (collision energy 7) and for ARG-D5 
(IS) was 180.12 > 75.07 (collision energy 55). Collision energies for ARG and ARG-D5 were 
set up not for optimal sensitivity, since concentration of ARG in CSF is high and very good 
sensitivity is not needed. They were optimized to eliminate crosstalk from ARG to ADMA 
and increase linear range of method for ARG. MS parameters were: Capillary (kV) 3.00; 
Cone (V) 30.00; Source Offset (V) 40.0; Source Temperature (°C) 150; Desolvation 
Temperature (°C) 550; Cone Gas Flow (L/Hr - Nitrogen) 150; Desolvation Gas Flow (L/Hr - 
Nitrogen) 1000; Collision Gas Flow (mL/Min) 0.15; Nebuliser Gas Flow (Bar) 7.00. 
Glutamine determination in microdialysates 
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Glutamine was assayed in microdialysate samples using HPLC with fluorescence detection 
after derivatization in a timed reaction with o-phthalaldehyde plus mercaptoethanol 
(Kilpatrick et al. 1991). The derivatized samples (50 µl) were injected onto a 150 × 4.6 mm, 5 
µm Hypersil ODS column with a mobile phase composed of 50 mM phosphate buffer 
(KH2PO4 / K2HPO4) containing 10% v/v methanol, pH 6.2 (solvent A), and methanol (solvent 
B). The methanol gradient was 20–70 % and the elution time was 20 min. The obtained 
values of extracellular neurotransmitter levels were not corrected for in vitro probe recovery. 
Arterial Spin Labeling (ASL) MRI 
The MRI (Magnetic Resonance Imaging) was conducted using a 9.4T horizontal scanner 
(BioSpec 94/20 USR, Bruker, Ettlingen, Germany) equipped with BGA6S gradient system. 
Images were acquired using 86 mm internal diameter birdcage RF coil (Bruker T12054V3) 
used for transmission while rat brain receive-only circularly polarized surface coil with 
integrated preamplifier and combiner used for signal reception (Bruker T11207V3). Perfusion 
measurement was performed 24 hours after the last dose of TAA or saline. An induction 
chamber with 2% isoflurane (Baxter, Poland) was used for anesthesia induction. During MRI 
isoflurane anesthesia was delivered via nosecone and maintained at 1.7% in a 1:2 oxygen/air 
mixture. Animal body temperature was maintained at 37°C using temperature controlled 
warming pad. Physiological parameters: ECG, respiration and body temperature were 
monitored with Monitoring and Gating System Model 1025 (SA Instruments Inc., Stony 
Brook, NY, USA). The animals were placed prone in the cradle throughout the imaging 
sessions lasting 2-2.5 hours with head stabilized using three point-fixation system (tooth-bar 
and ear plugs). Before the imaging 2 ml of saline was injected subcutaneously to prevent 
dehydration. Bolus injection of L-arginine (200 mg/kg/3ml) at a concentration capable of 
increasing brain L-arginine level as tested in microdialysis experiment, was delivered in the 
scanner with the use of an intraperitoneally placed cannula. Based on scout images two slice 
positions in the prefrontal cortex and cerebellum were selected for perfusion measurement. 
An exemplary location of these slices is shown in Fig. 5a. The measurements of the cerebral 
perfusion were performed in the following sequence: baseline assessment (pre) prefrontal 
cortex slice (24 min), cerebellum slice (24 min), L-arginine ip injection, 30 min interval and 
again prefrontal cortex slice (24 min), cerebellum slice (24 min) (post L-arginine) in the same 
geometry as the baseline. Immediately after MRI measurements, each rat received a lethal 
dose of pentobarbital (Biowet, Poland). 
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For tissue perfusion and T1 relaxation time measurement respiratory-gated FAIR-RARE 
(Flow-sensitive Alternating Inversion Recovery) sequence with the following parameters was 
used: repetition time (TR) 10000ms, echo time (TE) 5.1ms, number of averages (NA) 4, Rare 
Factor 72, field of view (FOV) 27x27mm, acquisition matrix (MTX) 128x128, resolution 
211x211µm, slice thickness 1.5mm, 14 inversion times (TI) ranging from 30 to 3000 ms, 
acquisition time 24min (approximately). 
Quantitative calculations of perfusion were performed with in-house written Matlab (The 
MathWorks Inc., Natick, MA, U.S.A.) script. In order to minimize possible fitting artifacts 
related to animal movement during a quite long measurement causing corresponding pixel 
shift on consecutive images with different TI, rigid transformation with Matlab imregister 
function was used to align all images within one scan to the first image in this scan. Then pre 
and post L-arg scans were aligned (second to first) as well. T1 relaxation time parametric 
maps were calculated pixel by pixel fitting inversion curve with Matlab nonlinear least-
squares solver function lsqcurvefit for the area (ROI) covering the brain, drawn by hand for 
each animal. Examples of such areas for prefrontal cortex and cerebellum slices, marked with 
yellow line on anatomic images are shown in Figure MRI2 (first and fourth column). Then 
blood flow maps were calculated according to Belle et al. (Belle et al. 1998) The examples of 
the perfusion maps are presented in Fig. 5c. Finally to get perfusion value for each animal in 
the prefrontal cortex and cerebellum, perfusion values were averaged from manually drawn 
ROIs shown in Fig. 5b. One rat from the TAA treated group was excluded from the 
calculations because it died during the magnetic resonance procedure. 
 
Statistical analysis 
All experiments were carried out with replicates in terms of animals per group as indicated. 
No test for outliers was conducted on the data obtained in the study. Data were tested for 
normal distribution with a Shapiro-Wilk test. Since they were normally distributed, a one-way 
or a repeated measures ANOVA with the post hoc Newman-Keuls or Tukey was performed. 
The data are presented as the mean ± standard error of the mean (mean ± SEM). A 
significance level of p < 0.05 was chosen for all tests. All statistical analyses were performed 
using the Statistica software package (Statsoft Inc., USA) and GraphPad Prism 7 (GraphPad 
Software, Inc., USA).  
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Results 
 
Isolated cerebral artery studies 
The effect of ADMA on the baseline MCA reactivity 
Incubation of MCAs from TAA rats in MOPS buffer containing ADMA at a dose of 2 µM 
resulted in a smaller initial vessel diameter measured directly after pressurizing (~78% of the 
control value, p<0.05 vs. Control+NH4 group), greater spontaneous myogenic tone 
development after 1 h stabilization (51%, p<0.001 vs. 33% in the control group) and higher 
vessel dilation in response to 20 mM KCl challenge (91%, p<0.01 vs. 43% in the control 
group) (Fig. 1 a-c). Moreover, a decreasing tendency in vessel diameter as well as increasing 
tendency to greater myogenic tone development and vessel dilation in response to 20 mM 
KCl were observed at the lower ADMA dose (1 µM) when compared to the control group 
(Fig. 1 a-c). 
 
The effect of extravascular administration of L-arginine on MCA diameter 
Extraluminal administration of L-arginine at a concentration of 100 µM resulted in a dilation 
of the MCA derived from TAA rats. The dose of 100 µM elicited a comparable vasodilation 
of the MCA in all TAA groups (~55 % of the maximum diameter,  p < 0.01; Fig. 2). 
 
The effect of systemic administration of L-arginine on cortical extracellular levels of L-
arginine and ADMA 
Administration of TAA (300 mg/kg/ip) resulted in a significant increase in extracellular 
ADMA concentration (to 260%, p < 0.01). The intraperitoneal injection of L-arginine (200 
mg/kg/3ml) did not significantly affect ADMA concentration both in control and TAA rats 
(Fig. 3a). The ANOVA for repeated measures revealed significant effects of treatment (F1,8 = 
9.70, p < 0.05). 
The intraperitoneal injection of L-arginine (200 mg/kg/3ml) resulted in a significant increase 
in cortical L-arginine level in TAA rats (to 185%, p < 0.001, Fig. 3b). The ANOVA for 
repeated measures revealed significant effects of treatment, time and treatment × time 
interaction (F1,8 = 8.03, p < 0.05; F3,24 = 9.63, p < 0.001, F3,24 = 5.29, p < 0.01, respectively). 
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The L-arginine/ADMA ratio was significantly decreased in TAA rats (to 68%, p < 0.05, Fig. 
3c). L-arginine administration increased this ratio to the level in the control group. The 
ANOVA for repeated measures revealed a significant effects of time (F3,24 = 6.44, p < 0.01). 
 
The effect of exogenous L-arginine on extracellular glutamine level in the prefrontal cortex 
of ALF rats 
Basal extracellular level of glutamine was significantly increased in the prefrontal cortex of 
TAA rats (~215 % of the control level). L-arginine (200 mg/kg/ip) significantly decreased 
extracellular glutamine (71% of the basal TAA level) as measured 120 min after injection 
(Fig. 4). Repeated measures ANOVA revealed a significant effect of group and L-arginine 
(F1,8 = 13.35 p < 0.01, F1,8 = 12.40 p < 0.01, respectively). 
 
Assessment of perfusion with arterial spin labeling: the effect of L-arginine 
Perfusion in the prefrontal cortex ROIs (Fig. 5b, yellow circles) was equal to 82 ± 5 
ml/min/100 g in the control group and decreased to 58 ± 5 ml/min/100 g in the TAA group. L-
arginine injection resulted in the increase in perfusion to 98 ± 7 ml/min/100 g in the control 
group and 66 ± 4 ml/min/100 g in the TAA group (Fig. 5d). Repeated measures ANOVA 
revealed significant effects of group and L-arginine stimulation (F1,10 = 15.44 p < 0.01; F1,10 = 
22,76, p < 0.001, respectively). 
Perfusion in the cerebellum ROIs (Fig. 5b, red circle) was equal to 133 ± 7 ml/min/100 g in 
the control group and decreased to 85 ± 5 ml/min/100 g in the TAA group. L-arginine 
injection increased perfusion to 100 ± 9 ml/min/100 g only in the TAA group (Fig. 5e). 
Repeated measures ANOVA revealed significant effects of group and L-arginine stimulation 
and group x L-arginine interaction (F1,10 = 15.75 p < 0.01; F1,10 = 5.88 , p < 0.05, F1,10 = 13.61, 
p < 0.01, respectively). 
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Discussion 
The present study demonstrates, to our knowledge for the first time, the reduced initial vessel 
diameter and impaired reactivity of pressurized middle cerebral arteries (MCAs) isolated from 
rats with thioacetamide (TAA)-induced acute liver failure (ALF), which supports ADMA 
contribution to the cerebral blood flow (CBF) decrease. Other new findings of the study 
include demonstration that (i) exogenous L-arginine application resulted in the excessive 
dilatation of MCAs from TAA rats ex vivo, (ii) intraperitoneal administration of L-arginine 
partially reversed the reduction of cerebral blood flow (CBF) in the cerebral cortex and 
cerebellum of TAA rats, and (iii) administration of L-arginine corrected the cerebral L-
arginine/ADMA ratio and decreased extracellular glutamine. These aspects deserve further 
comments. 
The MCA are a widely accepted tool for measurement of brain vascularity response to 
various stimuli (Faraci and Heistad 1990). What is important, the use of isolated vessels 
eliminates parenchymal influences and slow perfusion of the vessel while pressurization to 
the physiological level of blood pressure simulates in vivo conditions, and ensures proper 
myogenic tone and shear stress. MCAs from TAA rat brain were maintained in the 
environment that reproduced the status of vessels in vivo and contained pathophysiological 
concentration of ammonium ions and ADMA (equal to the plasma concentration in TAA rats,
 
Milewski et al. 2015). TAA vessels manifested a smaller initial vessel diameter, higher 
myogenic tone and larger vasodilation in viability test as compared to the vessels isolated 
from control rats. It may be assumed that smaller basal diameter of vessels incubated with 2 
µM ADMA resulted in their greater vasodilatory reserve and therefore greater response to K+ 
test. Previously, it was reported that concentration of ADMA that inhibited activity of brain 
NO synthase by 50 % in the cerebrum and cerebellum was approximately 2 µM (Faraci et al. 
1995). It is consistent with the present study showing that MCAs developed the increase in 
vascular tone in the presence of pathophysiologically elevated ADMA. Topical application of 
ADMA through cranial windows to rats constricted the basilar artery (BA) (Faraci et al. 
1995), whereas exogenously perfused ADMA evoked concentration- and endothelium-
dependent contractions of the human middle cerebral artery (Segarra et al. 1999). 
Consequently, exogenous ADMA-induced contraction of human middle cerebral artery rings 
was prevented by L-arginine (Chen et al. 2012). 
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In our study MCAs isolated from control and TAA rats responded differently to 
exogenous L-arginine application. Vessels isolated from TAA rats dilated by more than 50% 
of its maximum diameter as opposed to control MCAs which did not respond to L-arginine. 
This somewhat surprising result requires a detailed explanation. 
Studies reporting changes in the concentration of plasma L-arginine in ALF are not 
conclusive. Some reports found either unchanged (Tietge et al. 2002), reduced (Yagnik et al. 
2002) or increased (Cardounel et al. 2007) plasma L-arginine values. Furthermore, an 
increased level of plasma arginase during liver failure (Das et al. 2008) can additionally 
reduce the amount of available arginine, reducing endothelial NOS-mediated NO synthesis. In 
the TAA model, used in this study, plasma level of L-arginine was significantly decreased 
(Milewski 2017), which may provide a potential explanation of the above observation as 
masking of the effect of supplementation. 
The so far available data describing the effect of L-arginine on the cerebral blood 
vessels reactivity are also variable. L-arginine did not affect the diameter of intra-
parenchymal arterioles (Kimura et al. 1994), MCAs (Kovách et al. 1992) and BA (Rossitch et 
al. 1991) in vitro and had no effect on BA esistance (Faraci 1990) and CBF measured in vivo 
(Kovách et al. 1992; Faraci and Heistad 1992). In contrast, Rosenblum et al. (Rosenblum et 
al. 1990) and Morikawa et al.
 
(Morikawa et al. 1992) reported a dilation of pial arterioles in 
response to L-arginine in vivo and Kajita et al. (Kajita et al. 1995) observed dilation of the 
MCA, BA and anterior cerebral artery in vivo and parenchymal arterioles in vitro. In our study 
100 µM dose of L-arginine did not exert vasodilator response in control MCAs, while the 
response of those derived from TAA rats was substantial. Lack of the relaxation of the MCAs 
from control rats in response to L-arginine indicates that L-arginine is not rate-limiting for 
NOS activity, in contrast to its strong vasodilatory effect observed in MCAs isolated from 
TAA rats. It seems that the rate-limiting effect of L-arginine for NO synthesis may be due to 
the increased plasma ADMA and/or cellular uptake of L-arginine in TAA model. The later 
possibility is reasonable, since a significant increase in [
3
H]citrulline, a direct L-arginine 
precursor for de novo NO synthesis, into TAA cortical slices was previously reported 
(Zielińska et al. 2014). The former possibility deserves a comment. The increased L-
[H
3
]arginine uptake have been reported in ammonium acetate-affected cerebellar 
synaptosomes (Rao et al. 1997) and synaptosomal preparations from TAA rats (Albrecht et al. 
1990). MCAs isolated from control rats did not relax in response to L-arginine in the presence 
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of ammonium ions indicating that short-lasting hyperammonemia has a slight impact on the 
rate-limiting effect of L-arginine for NO synthesis. 
L-arginine may elevate NO production by increasing the substrate availability. 
However, its levels in plasma and cells are considerably higher than the eNOS Km for L-
arginine (Arnal et al. 1995; Harrison 1997). The fact that L-arginine drives NO production 
even when intracellular L-arginine levels are in excess is called the "arginine paradox" (Arnal 
et al. 1995; Harrison 1997; Böger and Ron 2005; Bode-Böger et al. 2007). It is assumed that 
in the presence of pathologically relevant concentrations of ADMA and physiological 
concentration of L-arginine, the endothelial NOS activity decreases, which results in NO 
formation rates below the physiological level. Therefore, in these conditions, supplementation 
of exogenous L-arginine competes with its inhibitor and restores the physiological L-
arginine/ADMA ratio (Bode-Boger et al. 2007). Thus, it appears that L-arginine may become 
a rate-limiting factor for NO synthesis in clinical conditions, but not in healthy individuals. 
Clinical and experimental evidence suggests that elevation of ADMA can cause a relative L-
arginine deficiency, even in the presence of physiological L-arginine levels. As ADMA is a 
competitive inhibitor of eNOS, its inhibitory action can be overcome by increasing the 
concentration of the enzyme's substrate, L-arginine (Böger and Ron 2005). 
However, in the present study, response of TAA-exposed vessels to 100 µM L-
arginine was independent of the short-term incubation with pathological concentration of 
ADMA. Strong vasodilation of MCAs in response to L-arginine was a common feature of all 
TAA rats independently of ADMA concentration in the buffer. One cannot exclude, however, 
that, to some extent, three-day exposure to elevated endogenous ADMA concentrations 
resulted in a prolonged substrate (L-arginine) deficiency and higher sensitivity of eNOS 
enzyme in brain vessels. The potential influence of ADMA presence in the buffer was 
probably masked by the enormous contractile response of TAA MCAs to exogenous L-
arginine. 
On the other hand, ADMA is not the only factor explaining the pronounced reactivity 
of TAA vessels in response to L-arginine. Aside from the L-arginine/ADMA balance, 
glutamine might be an important factor in the regulation of vascular response in HE condition. 
In vitro evidence in endothelial cells and perivascular nerves indicated that glutamine 
inhibited recycling of L-citrulline to L-arginine, thereby limiting L-arginine availability for 
NO production (Chen and Lee 1995; Lee et al. 1996). The mechanism of L-glutamine action 
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involves inhibition of argininosuccinate synthetase, an enzyme that is a part of the two-step 
recycling of L-citrulline to L-arginine for use by NOS (Sessa et al. 1990). Hyperammonemia, 
accompanying liver diseases is one of the pathophysiological conditions in which L-glutamine 
level increases (Cooper and Plum 1987). The increase in L-glutamine is prominent in ALF 
brain where glia cells are enriched in glutamine synthetase. The CBF response to hypercapnia 
is abolished during acute hyperammonemia (Durham et al. 1995; Takahashi et al. 1992). 
Inhibition of glutamine synthetase during hyperammonemia preserved the CBF (Takahashi et 
al. 1992) and pial arteriolar response to CO2 (Hirata et al. 1999) indicating that the impaired 
response was related to glutamine synthesis rather than to the increased concentration of 
ammonium ions. Glutamine presumably acts by limiting arginine availability because the 
vascular inhibitory effect required a few hours to develop and arginine infusion counteracted 
the vascular effect produced by the increased glutamine (Okada et al. 2000). Arnal et al. 
(Arnal et al. 1995) reported that L-arginine reversed L-glutamine's ability to inhibit NO 
release in bovine aortic endothelial cells and in rabbit aortic rings. In their study, L-arginine 
dose dependently enhanced the endothelium-dependent vascular relaxation only when L-
glutamine was present, suggesting a complex interplay between L-glutamine and receptor-
mediated activation of NO synthase. Moreover, this paradox may be influenced by 
endogenous NO synthase antagonists, such as ADMA (Harrison 1997). The present results 
indicated that extracellular concentration of L-glutamine was highly increased in the cerebral 
cortex of TAA rats while intraperitoneal injection of L-arginine significantly decreased it. It 
confirms that glutamine-induced vascular impairment may be overcome by the addition of 
exogenous L-arginine. 
Vascular reactivity is dependent on signals originating both from neurons and from 
astrocytes. Importantly, astrocytes contribute to the fine-tune regulation of cerebral vascular 
tone and CBF by producing and releasing both vasodilatory and vasoconstrictive compounds 
(Filosa et al. 2016). In addition, spatial regulation of astrocyte-induced dilations and 
constrictions contributing to the CBF changes were observed during fMRI recordings of brain 
activity (Metea and Newman 2006). The increased glutamine synthesis, beyond being the 
origin of astrocytic impairment under ALF state (Albrecht et al. 2017), might also impair 
neurovascular coupling as such. Thus, the balance of astrocyte-derived glutamine may 
contribute to the fine-tune regulation of cerebral vascular tone and CBF in ALF as well, 
however, more detailed studies are required. 
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We can suppose that the consequences of high ADMA brain concentration included 
the reduction of CBF both in the cerebral cortex and cerebellum, demonstrated in TAA rats. A 
significant impact of ADMA on CBF regulation under resting and pathologically changed 
conditions by NOS inhibition has been previously indicated (Iadecola 1993). Previously, we 
demonstrated that TAA administration resulted in a significant increase in the ADMA 
concentration in microdialysates of the prefrontal cortex, brain tissue homogenate and 
peripheral blood (Czarnecka et al. 2017, Milewski et al. 2015). Concentration of ADMA is 
higher in cerebellum and blood vessels than in other regions of the brain (Ueno et al. 1992), 
what may explain why in TAA rats L-arginine led to dilation of the MCAs and improved CBF 
more effectively in the cerebellum than in the prefrontal cortex. Large dilation of the MCAs 
compared to a slight CBF increase in the brain in response to L-arginine in TAA rats could be 
associated with L-arginine -related influence on the basal tone of cerebral blood vessels, 
which is greater in large arteries than arterioles (Faraci 1991). Therefore, regional differences 
in the cerebral response to L-arginine in control and TAA rats, observed in our study most 
likely resulted from variable vascularity pattern of the analyzed brain structures. 
Our microdialysis study revealed that systemic administration of L-arginine at the dose 
of 200 mg/kg, in spite of a significant increase in brain L-arginine content did not affect 
extracellular ADMA within 160 min after injection. However, the same dose of L-arginine 
effectively increased cerebral perfusion both in the prefrontal cortex and cerebellum of TAA-
treated rats, as well as in the prefrontal cortex of the control rats. Thus, it can be assumed that 
the beneficial effect of L-arginine administration was likely due to de novo NO synthesis 
predominantly by endothelial NOS, the most effective isoform synthesizing NO
 
in the 
vasculature (Moncada and Higgs 2006). On the other hand, it cannot be excluded that the 
elevated ADMA level may aggravate the disturbances observed in the cerebral perfusion of 
ALF rats. The most likely scenario might be that ADMA, in combination with hypocapnia 
(Strauss 2007), increased intracranial pressure and hypotension (Filho et al. 2006), and, 
therefore, contributed to the decreased cerebral perfusion at this stage of disease. L-arginine is 
postulated as a therapy in vascular diseases accompanied by increased ADMA concentration 
(Czarnecka et al. 2017). However, it still remains an open question to what extent it is 
achievable to modulate pathologically increased ADMA, with the aim of improving the 
patients’ condition. Importantly, our study demonstrates that beneficial effect of L-arginine on 
CBF was observed even under constantly raised ADMA level. 
Conclusion 
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The essential finding of the present study is that extraluminal L-arginine application evokes a 
pronounced vasodilation of the isolated MCAs from rats with ALF compared with control. 
The effect is most likely associated with limited availability of L-arginine caused by a high 
cerebral ADMA and glutamine concentrations accompanying ALF. The concomitantly 
reduced CBF in the cerebral cortex and cerebellum, partially reversed by the intraperitoneal 
administration of L-arginine, restored L-arginine/ADMA ratio and considerable reduction of 
glutamine concentration seem to confirm that disturbed nitrergic signaling plays a role in 
impaired cerebral perfusion during ALF. 
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Figure captions 
Figure 1. Initial vessel diameter (a) Development of myogenic tone (b) and dilation in 
response to 20 mM KCl (c) of the isolated MCAs. All data are presented as the mean ± SEM; 
N = 5 for each group. **p<0.01 ***p<0.001 vs. Control;
 #
p<0.05, 
##
p<0.01, 
###
p<0.001 vs. 
Control+NH4; 
∆∆
p<0.01 vs. TAA+NH4 group. 
 
Figure 2. Response of the MCA to L-arginine (100 µM). Dilation is expressed as a percentage 
of maximum diameter. Data are expressed as the means ± S.E.M; N = 5 for each group except 
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N=4 for TAA+NH4+ADMA 2 µM group. **p<0.01 vs. Control L-arg 100 µM; #p<0.05; 
##p<0.01 vs. Control+NH4 L-arg 100 µM. 
 
Figure 3. The extracellular levels of ADMA (a) L-arginine (b) and L-arginine/ADMA ratio 
(c) in the prefrontal cortex of control and TAA rats: the effect of intraperitoneal 
administration of exogenous L-arginine (200 mg/kg). The results are presented as the mean ± 
SEM, N = 5 for each group for each time point. *p<0.05 vs. Control; # p<0.05, ### p<0.001 
vs. TAA. 
 
Figure 4. The extracellular levels of L-glutamine in the prefrontal cortex of control and TAA 
rats: the effect of intraperitoneal administration of exogenous L-arginine (200 mg/kg). The 
results are presented as the mean ± SEM, N = 5 for each group for each time point. ** p<0.01 
vs. control basal level; ## p<0.01 vs. TAA basal level. 
 
Figure 5. Slice location for perfusion measurement on sagittal and coronal brain images. 
Prefrontal cortex slice is marked in yellow, cerebellum slice is marked in red (a). Example of 
manually placed ROIs in prefrontal cortex (yellow line) and cerebellum (red line) used for 
calculation of average perfusion (b). Examples of perfusion maps obtained in prefrontal 
cortex (top row) and cerebellum (bottom row) for control (left) and TAA group (right) 
respectively. CBF map was calculated in ROI marked with yellow line on anatomic images 
(c). Quantitative data for CBF measurement before and after L-arginine administration in 
control and TAA rats in the prefrontal cortex (d) and cerebellum (e). All data are presented as 
the mean ± SEM; N = 6 for each group for each time point. * p<0.05 **p<0.01 vs. Control 
pre; # p<0.05, ## p<0.01 ### p<0.001 vs. TAA pre; ∆p<0.05, ∆∆ p<0.01 vs. Control post. 
Page 27 of 35 Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
	

  
	

		
 
!
	
					


 	

 	
	



  		
	"		
	"

!
  #

 		
	

  $			"	
% 	


		
	
 
  &
	"		'	


  (		(		)
	
(	)	!
  *		
  $			"(	"

!


  +'	)
,		

)	!
  +			'	
!
  -
!
  $			""

		


		


 
  $								
	
	(	"	
	

"
  . "%%	)	
'	%
  ."			
	

	#



		$			

	
 

%		
  "		/			
"""	
!					"
	%	"	
!0
  1"	"$(!	'	
"
'	"
!
  '	"%(""	
"'	
#



  2	%".	)1334
)
2
	
	
)%		"

)%		

		
		!
  #

  #







  5






  #




  67




  #)	'	



  67

  #) 89 85
&


  9)67


  
  	 	
		
	

Page 28 of 35Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review


 	

 	
	
  +		%	
4

	"
  :
		%

  $				%				%"
		
  			

		;<3!
	
%
  


	%


  3
	

		
	

				
&
  +	2	
	)		

	"1!"		
!
  			"	%

	%	
	
  -
"
	=)	
	)
	)

)	"

	)	
		4
	
!
  +	"%!
  +)	%)	(!
  +%	"""		)
	"
		)

!



  

  # 67




  # 67
%
'


  $)	
  $
"	)	

)1"		
!
  $		"	
			
  $			"	%	"
%			:>
			:		
:>:=			 		!
o "		)	",
	"	
	
	
  $'
  
  +	

  -
	%")
"!
  -
%	"	)	%)
		
)		!
  +" 				
  #
  #

  


  

  #
  #
  #

  #
  #


  #
	




	


$	$
$	
  1	"					
"%
  $"%	
	"%!"		
)
")
!
  1%	
	
o 					
	"	
			
o 		""

o '

		
  '	
  .'	 

  :	"""	"
			
  67 68











Page 29 of 35 Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review

Page 30 of 35Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 1. Initial vessel diameter (a) Development of myogenic tone (b) and dilation in response to 20 mM 
KCl (c) of the isolated MCAs. All data are presented as the mean ± SEM; N = 5 for each group. **p<0.01 
***p<0.001 vs. Control; #p<0.05, ##p<0.01, ###p<0.001 vs. Control+NH4; ∆∆p<0.01 vs. TAA+NH4 
group.  
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Figure 2. Response of the MCA to L-arginine (100 µM). Dilation is expressed as a percentage of maximum 
diameter. Data are expressed as the means ± S.E.M; N = 5 for each group except N=4 for TAA+NH4+ADMA 
2 µM group. **p<0.01 vs. Control L-arg 100 µM; #p<0.05; ##p<0.01 vs. Control+NH4 L-arg 100 µM.  
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Figure 3. The extracellular levels of ADMA (a) L-arginine (b) and L-arginine/ADMA ratio (c) in the prefrontal 
cortex of control and TAA rats: the effect of intraperitoneal administration of exogenous L-arginine (200 
mg/kg). The results are presented as the mean ± SEM, N = 5 for each group for each time point. *p<0.05 
vs. Control; # p<0.05, ### p<0.001 vs. TAA.  
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Figure 4. The extracellular levels of L-glutamine in the prefrontal cortex of control and TAA rats: the effect of 
intraperitoneal administration of exogenous L-arginine (200 mg/kg). The results are presented as the mean 
± SEM, N = 5 for each group for each time point. ** p<0.01 vs. control basal level; ## p<0.01 vs. TAA 
basal level  
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Figure 5. Slice location for perfusion measurement on sagittal and coronal brain images. Prefrontal cortex 
slice is marked in yellow, cerebellum slice is marked in red (a). Example of manually placed ROIs in 
prefrontal cortex (yellow line) and cerebellum (red line) used for calculation of average perfusion (b). 
Examples of perfusion maps obtained in prefrontal cortex (top row) and cerebellum (bottom row) for control 
(left) and TAA group (right) respectively. CBF map was calculated in ROI marked with yellow line on 
anatomic images (c). Quantitative data for CBF measurement before and after L-arginine administration in 
control and TAA rats in the prefrontal cortex (d) and cerebellum (e). All data are presented as the mean ± 
SEM; N = 6 for each group for each time point. * p<0.05 **p<0.01 vs. Control pre; # p<0.05, ## p<0.01 
### p<0.001 vs. TAA pre; ∆p<0.05, ∆∆ p<0.01 vs. Control post.  
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